| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
2'-Deoxy-2'-fluoro-bD-arabinocytidine targets nucleotide metabolism and DNA synthesis pathways. As a purine nucleoside analog, it mimics the structure of natural nucleosides and can be incorporated into DNA or interfere with nucleotide metabolism. The fluorine substitution at the 2'-position may enhance the compound's metabolic stability and resistance to enzymatic degradation. The anticancer mechanism depends on the inhibition of DNA synthesis and the induction of apoptosis.
|
|---|---|
| ln Vitro |
In vitro, 2'-Deoxy-2'-fluoro-bD-arabinocytidine functions as a purine nucleoside analog that can interfere with cellular metabolism. As a purine nucleoside analog, it exhibits broad-spectrum anticancer effects. The compound's activity as a nucleoside analog allows it to be incorporated into nucleic acids or to interfere with nucleotide metabolism, leading to inhibition of cell proliferation in cancer cells.
|
| ln Vivo |
In vivo activity data for 2'-Deoxy-2'-fluoro-bD-arabinocytidine are limited. As a purine nucleoside analog with broad-spectrum anticancer activity, the compound may have potential for in vivo studies in animal models of cancer. Typical in vivo studies for nucleoside analogs involve administration to tumor-bearing mouse models, with assessment of tumor growth inhibition and survival.
|
| Enzyme Assay |
For non-cellular in vitro assays, 2'-Deoxy-2'-fluoro-bD-arabinocytidine is evaluated for its interactions with enzymes involved in nucleotide metabolism. The compound may be tested as a substrate or inhibitor of nucleoside kinases, polymerases, or other enzymes. Enzyme inhibition or incorporation assays may be performed to characterize its mechanism of action.
|
| Cell Assay |
For in vitro cellular assays, 2'-Deoxy-2'-fluoro-bD-arabinocytidine is tested in cancer cell lines to assess its antiproliferative effects. Cells are treated with serial dilutions of the compound, and cell viability and proliferation are measured using standard assays. The compound's effects on DNA synthesis, cell cycle progression, and induction of apoptosis are evaluated.
|
| Animal Protocol |
For in vivo animal studies, 2'-Deoxy-2'-fluoro-bD-arabinocytidine would typically be evaluated in xenograft mouse models of cancer. Mice bearing established tumors are treated with the compound via oral or intraperitoneal administration. Tumor volumes are measured regularly, and tumor growth inhibition is calculated. Body weight and general health are monitored to evaluate tolerability.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2'-Deoxy-2'-fluoro-bD-arabinocytidine are limited. As a nucleoside analog with a molecular weight of 245.21, it is expected to have moderate oral bioavailability and may be transported into cells via nucleoside transporters. The fluorine substitution may enhance metabolic stability. Further pharmacokinetic studies would be needed to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2'-Deoxy-2'-fluoro-bD-arabinocytidine are limited. As a nucleoside analog, it may have dose-dependent toxicities affecting rapidly dividing cells. Comprehensive toxicology studies would be required for therapeutic development. The compound is for research use only and not for human use.
|
| References | |
| Additional Infomation |
2'-Deoxy-2'-fluoro-bD-arabinocytidine is a purine nucleoside analog with a molecular formula of C₉H₁₂FN₃O₄ and a molecular weight of 245.21. Purine nucleoside analogs have broad-spectrum anticancer effects targeting indolent lymphoid malignancies. The anticancer mechanism depends on the inhibition of DNA synthesis and the induction of apoptosis. The fluorine substitution at the 2'-position may enhance metabolic stability.
|
| Molecular Formula |
C9H12FN3O4
|
|---|---|
| Molecular Weight |
245.21
|
| Exact Mass |
245.081
|
| CAS # |
56632-83-8
|
| PubChem CID |
151382
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
500.1±60.0 °C at 760 mmHg
|
| Flash Point |
256.2±32.9 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.697
|
| LogP |
-1.26
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
386
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)F
|
| InChi Key |
NVZFZMCNALTPBY-PXBUCIJWSA-N
|
| InChi Code |
InChI=1S/C9H12FN3O4/c10-6-7(15)4(3-14)17-8(6)13-2-1-5(11)12-9(13)16/h1-2,4,6-8,14-15H,3H2,(H2,11,12,16)/t4-,6+,7-,8-/m1/s1
|
| Chemical Name |
4-amino-1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0781 mL | 20.3907 mL | 40.7814 mL | |
| 5 mM | 0.8156 mL | 4.0781 mL | 8.1563 mL | |
| 10 mM | 0.4078 mL | 2.0391 mL | 4.0781 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
